Cytopathic viruses for therapy and prophylaxis of neoplasia
AssigneeOnyx Pharmaceuticals, Inc.
InventorFrancis McCormick
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.
Claims5
A method for ablating neoplastic cells in a cell population, comprising the steps of:
- contacting under infective conditions (1) a recombinant replication deficient adenovirus lacking an expressed viral oncoprotein which binds a functional p53 tumor suppressor gene product, with (2) a cell population comprising non-neoplastic cells containing said functional p53 tumor suppressor gene product which forms a bound complex with a viral oncoprotein and neoplastic cells lacking said functional p53 tumor suppressor gene product, thereby generating an infected cell population, and a chemotherapeutic.
An anti-neoplastic composition for therapy of neoplastic disease, comprising a therapeutically effective dosage of a recombinant replication deficient adenovirus, said virus lacking an expressed viral oncoprotein which binds a functional p53 tumor suppressor gene product, and which replicates in neoplastic cells that substantially lack functional p53, and a chemotherapeutic.
Dependencies are inferred from the claim text.